[The findings showed that PBT434 passed the blood-brain barrier and inhibited the alpha-synuclein protein which when aggregated in the brain is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for treating these neurodegenerative diseases.]
More info from the P1.
PBT434 inhibits alpha- synuclein in the brain.
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $71.15K | 17.43M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 101 | 87272775 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24185511 | 15 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |